Adult Medulloblastoma
Conditions
Brief summary
This phase II trial is studying how well vismodegib works in treating adult patients with recurrent or refractory medulloblastoma. Vismodegib may slow the growth of tumor cells and may be an effective treatment for medulloblastoma.
Detailed description
PRIMARY OBJECTIVES: I. To estimate the efficacy of GDC-0449 (vismodegib) treatment for adult patients with recurrent or refractory medulloblastoma, as measured by the objective response rates for patients without (Stratum A) and with (Stratum B) evidence of activation of Sonic Hedgehog (SHH) signaling pathway tumors. SECONDARY OBJECTIVES: I. To assess the safety and tolerability of GDC-0449 administered on a once daily schedule. II. To estimate the duration of objective response and progression-free survival (PFS). III. To characterize the pharmacokinetics (plasma and cerebrospinal fluid) of GDC-0449 in adults with refractory medulloblastoma. IV. To document pathologic and genomic methods to identify CNS tumors with activation of the PTCH/SHH pathway. V. To describe the objective responses observed in patients whose pathologic assessment of tumor result in unknown (Stratum C) evidence of activation of Sonic Hedgehog (SHH) signaling pathway tumors. OUTLINE: This is a multicenter study. Patients are stratified according to PTCH/Sonic Hedgehog signaling pathway activation (inactivated vs activated vs unknown). Patients receive vismodegib orally (PO) once daily on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up periodically for up to 12 months.
Interventions
OTHERPharmacological Study
Correlative studies
DRUGVismodegib
Given PO
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with a histologically confirmed diagnosis of medulloblastoma (including posterior fossa PNET) that is recurrent, progressive, or refractory to standard therapy and for which there is no known curative therapy are eligible; there must be evidence of residual measurable disease or lesion in pre-study MRI as described in section; patients with spinal disease that is measurable will be eligible * The diagnosis should be confirmed at the treating institution and tissue (either from the diagnosis or relapse or preferably from both time points) must be available for biological studies * Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to registration; this is to be documented in the database * Eastern Cooperative Oncology Group (ECOG) performance status 0- 2 * No other myelosuppressive chemotherapy or immunotherapy within 4 weeks prior to study entry (6 weeks if prior nitrosourea) * Decadron dose should also be stable or decreasing for at least 1 week (7days) prior to starting therapy * Radiation therapy (XRT) \>= 3 months prior to study entry for craniospinal irradiation (\>= 23 Gy); \>= 8 weeks for local irradiation to primary tumor; \>= 2 weeks prior to study entry for focal irradiation for symptomatic metastatic sites * Off all colony stimulating factors \>= 1 week prior to study entry (GCSF, GM CSF, erythropoietin) * Absolute neutrophil count (ANC) \>= 1000/μL * Platelet count \>= 50,000/uL (transfusion independent) * Hemoglobin \>= 8.0 gm/dL (may receive RBC transfusions) * Creatinine clearance or radio-isotope GFR \>= 70ml/min/1.73 m2 or * A serum creatinine =\< 2.0 mg/dL * Total bilirubin =\< 1.5 x upper limit of normal (ULN) for age * Serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase \[ALT\]) =\< 2.5 x institutional ULN * Serum glutamic-oxalacetic transaminase (SGOT) (aspartate aminotransferase \[AST\]) =\< 2.5 times institutional ULN * Serum albumin \>= 2.5 g/dL * Patient must have recovered from the significant acute toxicities of all prior therapy before entering this study and meet all other eligibility criteria * Pregnancy should be avoided for 12 months after the last dose of GDC-0449 for females of child-bearing potential; female patients of childbearing potential must not be pregnant or breast-feeding; female patients of childbearing potential must have a negative serum or urine pregnancy test within 24 hours prior to beginning treatment * Women of childbearing potential are required to use 2 forms of acceptable contraception, including one barrier method during participation in the study and for the 12 months following the last dose; for medical or personal reasons, 100% commitment to abstinence is considered an acceptable form of birth control. All patients should receive contraceptive counseling either by the investigator, or by an OB/gynecologist or other physician who is qualified in this area of expertise; prior to dispensing GDC-0449, the investigator must confirm and document the patient's use of two contraceptive methods, dates of negative pregnancy test, and confirm the patient's understanding of the of GDC-0449 to cause spontaneous abortion or birth defects * Signed informed consent according to institutional guidelines must be obtained
Exclusion criteria
* Patients with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction), that would compromise the patient's ability to tolerate protocol therapy or would likely interfere with the study procedures or results * Patients receiving any other anticancer or investigational drug therapy * Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy * Life expectancy \< 12 weeks as determined by treating physician * Inability to swallow capsules * Prior treatment with GDC-0449 or other antagonists of the HH pathway * Malabsorption syndrome or other condition that would interfere with enteral absorption * History of congestive heart failure * History of ventricular arrhythmia requiring medication * Uncontrolled hypocalcemia, hypomagnesemia, hyponatremia or hypokalemia defined as less than the lower limit of normal for the institution despite adequate electrolyte supplementation * Congenital long QT syndrome
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response (CR+PR) Sustained for ≥ 8 Weeks | Up to 12 months | Objective response is either a complete response or a partial response sustained for 8 weeks in a patient. The objective response rate will be reported separately for patients of each stratum. CR is complete disappearance of all enhancing tumor. PR is \>= 50% reduction in tumor size. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival | From start of treatment up to 2 years | Progression-free survival (PFS) is measured from the date of initial treatment with GDC-0449 until the earliest of progression or death on study. PFS is censored at the last tumor assessment date for patients without disease progression who have not died within 30 days of last exposure to study treatment. Kaplan-Meier method is used to estimate the progression-free survival. |
| Duration of Objective Response | From start of treatment up to 2 years | The duration of objective response is measured from the initial scan documenting complete or partial response that was subsequently confirmed until the earlier of documented progression or death on study. Duration of objective response is censored at the last tumor assessment date for patients without disease progression who have not died within 30 days of last exposure to study treatment. |
| Pharmacokinetic Parameters of Vismodegib, CSF Penetration | up to 12 month | The estimated median of cerebrospinal fluid (CSF) drug penetration is reported when expressed as an AUC ratio of CSF vismodegib to that of unbound drug in plasma. |
Countries
United States
Participant flow
Recruitment details
This study was distributed to the sites on June 18, 2009, and received the first IRB approval on July 20, 2009. The study was closed to accrual on December 07, 2012. Thirty two (32) patients have been enrolled to the study, Last patient went off treatment in October 2013.
Pre-assignment details
Total 32 patients were registered on this study, 8 in Stratum A, 21 in Stratum B and 3 in Stratum C. One patient in Stratum B was declared ineligible.
Participants by arm
| Arm | Count |
|---|---|
| Stratum A (PTCH/SHH Pathway Inactivated) Adult patients with recurrent or refractory medulloblastoma who have tumors without evidence of PTCH/SHH pathway activation | 8 |
| Stratum B (PTCH/SHH Pathway Activated) Adult patients with recurrent or refractory medulloblastoma who have tumors with evidence of activation of the PTCH/SHH pathway | 20 |
| Stratum C (Unknown PTCH/SHH Pathway Activation) Adult patients with recurrent or refractory medulloblastoma registered on protocol whose tumor assay is inconclusive as to whether or not the PTCH/SHH pathway is activated or whose tissue sample is inadequate to assess the PTCH/SHH pathway status | 3 |
| Total | 31 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Progression/Relapse | 8 | 20 | 3 |
Baseline characteristics
| Characteristic | Stratum A (PTCH/SHH Pathway Inactivated) | Stratum B (PTCH/SHH Pathway Activated) | Stratum C (Unknown PTCH/SHH Pathway Activation) | Total |
|---|---|---|---|---|
| Age, Continuous | 23.8 years | 32.0 years | 32.9 years | 30.3 years |
| Diagnosis Desmoplastic medulloblastoma | 0 participants | 1 participants | 0 participants | 1 participants |
| Diagnosis Medulloblastoma, NOS | 8 participants | 18 participants | 3 participants | 29 participants |
| Diagnosis Primitive neuroectodermal tumor | 0 participants | 1 participants | 0 participants | 1 participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 1 Participants | 1 Participants | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 7 Participants | 18 Participants | 2 Participants | 27 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 1 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 3 Participants | 0 Participants | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 1 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) White | 7 Participants | 16 Participants | 3 Participants | 26 Participants |
| Region of Enrollment United States | 8 participants | 20 participants | 3 participants | 31 participants |
| Sex: Female, Male Female | 2 Participants | 9 Participants | 2 Participants | 13 Participants |
| Sex: Female, Male Male | 6 Participants | 11 Participants | 1 Participants | 18 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 8 / 8 | 20 / 20 | 3 / 3 |
| serious Total, serious adverse events | 5 / 8 | 12 / 20 | 3 / 3 |
Outcome results
Primary
Objective Response (CR+PR) Sustained for ≥ 8 Weeks
Objective response is either a complete response or a partial response sustained for 8 weeks in a patient. The objective response rate will be reported separately for patients of each stratum. CR is complete disappearance of all enhancing tumor. PR is \>= 50% reduction in tumor size.
Time frame: Up to 12 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Stratum A (PTCH/SHH Pathway Inactivated) | Objective Response (CR+PR) Sustained for ≥ 8 Weeks | 0 proportion of participants |
| Stratum B (PTCH/SHH Pathway Activated) | Objective Response (CR+PR) Sustained for ≥ 8 Weeks | 0.15 proportion of participants |
| Stratum C (Unknown PTCH/SHH Pathway Activation) | Objective Response (CR+PR) Sustained for ≥ 8 Weeks | 0 proportion of participants |
Secondary
Duration of Objective Response
The duration of objective response is measured from the initial scan documenting complete or partial response that was subsequently confirmed until the earlier of documented progression or death on study. Duration of objective response is censored at the last tumor assessment date for patients without disease progression who have not died within 30 days of last exposure to study treatment.
Time frame: From start of treatment up to 2 years
Population: Patients with sustained objective response
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Stratum A (PTCH/SHH Pathway Inactivated) | Duration of Objective Response | 4.59 months |
Secondary
Pharmacokinetic Parameters of Vismodegib, CSF Penetration
The estimated median of cerebrospinal fluid (CSF) drug penetration is reported when expressed as an AUC ratio of CSF vismodegib to that of unbound drug in plasma.
Time frame: up to 12 month
Population: The calculation of drug penetration is based on patients who had the course 1 plasma and CSF drug concentration data
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Stratum A (PTCH/SHH Pathway Inactivated) | Pharmacokinetic Parameters of Vismodegib, CSF Penetration | 0.12 ratio |
Secondary
Progression-free Survival
Progression-free survival (PFS) is measured from the date of initial treatment with GDC-0449 until the earliest of progression or death on study. PFS is censored at the last tumor assessment date for patients without disease progression who have not died within 30 days of last exposure to study treatment. Kaplan-Meier method is used to estimate the progression-free survival.
Time frame: From start of treatment up to 2 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Stratum A (PTCH/SHH Pathway Inactivated) | Progression-free Survival | 1.64 months |
| Stratum B (PTCH/SHH Pathway Activated) | Progression-free Survival | 2.76 months |
| Stratum C (Unknown PTCH/SHH Pathway Activation) | Progression-free Survival | 1.48 months |